No place for Wee1 in Astra’s synthetic lethality work
Wee1 competitors including Zentalis might look with trepidation on Astra and Roche’s recent moves into ATR inhibition.
Scholar Rock’s quest for a better TGF-β drug
Biomarkers and precise targeting could help the anti-TGF-β1 antibody SRK-181 succeed where bintrafusp failed, the group hopes.
Biopharma’s stock market winners of 2021 revealed
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
The quest for efficacy in pancreatic cancer
Late-stage therapies from Fibrogen, Tyme and Novartis need to avoid the same pitfalls as Erytech and Rafael.
Treme climbs a new mountain
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
